Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Enterprise Value: 2017-2025

Historic Enterprise Value for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $3.6 billion.

  • Protagonist Therapeutics' Enterprise Value rose 63.00% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 108.97%. This contributed to the annual value of $1.9 billion for FY2024, which is 91.81% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Enterprise Value stood at $3.6 billion, which was up 24.56% from $2.9 billion recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Enterprise Value ranged from a high of $3.6 billion in Q3 2025 and a low of $92.9 million during Q2 2022.
  • Moreover, its 3-year median value for Enterprise Value was $1.5 billion (2024), whereas its average is $1.8 billion.
  • As far as peak fluctuations go, Protagonist Therapeutics' Enterprise Value slumped by 94.78% in 2022, and later skyrocketed by 1,264.29% in 2023.
  • Protagonist Therapeutics' Enterprise Value (Quarterly) stood at $1.3 billion in 2021, then crashed by 77.06% to $299.4 million in 2022, then surged by 227.63% to $980.9 million in 2023, then surged by 91.81% to $1.9 billion in 2024, then soared by 63.00% to $3.6 billion in 2025.
  • Its Enterprise Value stands at $3.6 billion for Q3 2025, versus $2.9 billion for Q2 2025 and $2.4 billion for Q1 2025.